P. Badorrek

发表

The first‐in‐human study of CNTO 7160, an anti‐interleukin‐33 receptor monoclonal antibody, in healthy subjects and patients with asthma or atopic dermatitis

Tong-Yuan Yang, B. Frederick, F. Baribaud, 2020, British journal of clinical pharmacology.

Effects of Anti-IL-13 (Novartis QAX576) on Inflammatory Responses Following Nasal Allergen Challenge (NAC).

N. Krug, J. Hohlfeld, J. Westwick, 2009, ATS 2009.

Pollen starch granules in bronchial inflammation.

N. Krug, J. Hohlfeld, W. Koch, 2012, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Efficacy and Safety of a Drug-Free, Barrier-Forming Nasal Spray for Allergic Rhinitis: Randomized, Open-Label, Crossover Noninferiority Trial

J. Hohlfeld, F. Fais, J. Hohlfeld, 2021, International Archives of Allergy and Immunology.

Safety, efficacy and repeatability of a novel house dust mite allergen challenge technique in the Fraunhofer allergen challenge chamber

N. Krug, J. Hohlfeld, T. Framke, 2016, Allergy.

Efficacy and safety of a novel nasal steroid, S0597, in patients with seasonal allergic rhinitis.

N. Krug, J. Hohlfeld, A. Joshi, 2015, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Predictors and associations of the persistent airflow limitation phenotype in asthma: a post-hoc analysis of the ATLANTIS study.

J. Wedzicha, J. Vonk, K. Bønnelykke, 2022, The Lancet. Respiratory medicine.

Lung pharmacokinetics of inhaled and systemic drugs: A clinical evaluation

J. Hohlfeld, O. Holz, U. Eriksson, 2021, British journal of pharmacology.

Exacerbation of atopic dermatitis on grass pollen exposure in an environmental challenge chamber.

N. Krug, J. Hohlfeld, A. Heratizadeh, 2015, The Journal of allergy and clinical immunology.

Effects of Recombinant Human Angiotensin-Converting Enzyme 2 on Response to Acute Hypoxia and Exercise: A Randomised, Placebo-Controlled Study

J. Hohlfeld, D. Budd, A. Lazaar, 2021, Pulmonary Therapy.

Investigating the effect of TRPV4 inhibition on pulmonary-vascular barrier permeability following segmental endotoxin challenge.

J. Hohlfeld, D. Behm, A. Lazaar, 2020, Pulmonary pharmacology & therapeutics.

CRTH2 Antagonist, BI 671800 (BI), Reduces Nasal Symptoms And Inhibits Nasal Cytokines And Eosinophils In SAR Patients Exposed To Grass Pollen In An Environmental Challenge Chamber (ECC)

N. Krug, J. Hohlfeld, C. Wood, 2012, ATS 2012.

Specificity and reproducibility of nasal biomarkers in patients with allergic rhinitis after allergen challenge chamber exposure.

N. Krug, J. Hohlfeld, W. Koch, 2017, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Phase 1 pharmacokinetics and phase 3 efficacy of testosterone nasal gel in subjects with seasonal allergies.

J. Hohlfeld, A. Rogol, P. Badorrek, 2018, Canadian Urological Association journal = Journal de l'Association des urologues du Canada.

Validation of an environmental exposure unit for controlled human inhalation studies with grass pollen in patients with seasonal allergic rhinitis

N. Krug, J. Hohlfeld, M. Larbig, 2003, Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology.

A combination of cetirizine and pseudoephedrine has therapeutic benefits when compared to single drug treatment in allergic rhinitis.

N. Krug, J. Hohlfeld, H. Hecker, 2009, International journal of clinical pharmacology and therapeutics.

Anti-allergic drug testing in an environmental challenge chamber is suitable both in and out of the relevant pollen season.

N. Krug, A. Sousa, J. Hohlfeld, 2011, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Efficacy of the oral chemoattractant receptor homologous molecule on TH2 cells antagonist BI 671800 in patients with seasonal allergic rhinitis.

N. Krug, J. Hohlfeld, C. Wood, 2014, The Journal of allergy and clinical immunology.

Experience with an allergen challenge chamber for clinical trials in allergic rhinitis

N. Krug, J. Hohlfeld, P. Badorrek, 2012 .

Occupational exposure to veterinary antibiotics: Pharmacokinetics of enrofloxacin in humans after dermal, inhalation and oral uptake - A clinical study.

J. Hohlfeld, T. Hansen, K. Bluemlein, 2023, Environmental toxicology and pharmacology.

Basic skin therapy effects on skin inflammation and microbiome composition in patients with atopic dermatitis after challenges with grass pollen

A. Heratizadeh, L. Moitinho-Silva, J. Hohlfeld, 2022, Journal of the European Academy of Dermatology and Venereology : JEADV.

The Effect of a Thixotropic Nasal Gel on Nasal Symptoms and Inflammatory Biomarkers in Seasonal Allergic Rhinitis

J. Hohlfeld, P. Badorrek, C. Mattern, 2020, International Archives of Allergy and Immunology.

Phase I Characterization of the Novel Cathepsin C Inhibitor BI 1291583

J. Hohlfeld, A. Eleftheraki, C. Diefenbach, 2022, C93. CLINICAL TRIALS IN CHRONIC LUNG DISEASE.

The effect of bradykinin 1 receptor antagonist BI 1026706 on pulmonary inflammation after segmental lipopolysaccharide challenge in healthy smokers.

K. Hohl, Abhya Gupta, W. Seibold, 2023, Pulmonary pharmacology & therapeutics.

Pharmacokinetics of Nasal Esketamine in Patients with Allergic Rhinitis with and Without Nasal Decongestant Pretreatment and in Healthy Subjects with and Without Nasal Corticosteroid Pretreatment

J. Hohlfeld, Jaskaran Singh, M. De Meulder, 2023, Clinical Pharmacokinetics.

Investigating the effect of TRPV4 inhibition on pulmonary-vascular barrier permeability following segmental endotoxin challenge.

J. Hohlfeld, D. Behm, A. Lazaar, 2020, Pulmonary pharmacology & therapeutics.

Safety, pharmacokinetics and pharmacodynamics of a novel anti-asthmatic drug, XC8, in healthy probands.

B. Ferko, J. Romanova, Meike Müller, 2019, Pulmonary pharmacology & therapeutics.

The preclinical and phase 1 development of the novel oral cathepsin C inhibitor BI 1291583

P. Badorrek, James D. Chalmers, Claudia Diefenbach, 2024, ERJ open research.